Should I buy Elevance Health (ELV) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $404 (+1.2 %), call made on June 5, 2026, maturing on June 5, 2027 (84 d ago).
Firm-by-firm track record on Elevance Health
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Deutsche Bank | 67 % | +11.7 % | 9 | $498 +25% |
| Morgan Stanley | 70 % | +10.8 % | 23 | $404 +1% |
| Jefferies | 70 % | +10.4 % | 10 | $391 -2% |
| UBS | 62 % | +10.1 % | 8 | $460 +15% |
| Barclays | 61 % | +3.0 % | 18 | $457 +15% |
| Wells Fargo | 47 % | +2.7 % | 15 | $473 +19% |
| Truist Securities | 55 % | +2.5 % | 11 | $475 +19% |
| JP Morgan | 62 % | +1.0 % | 8 | $476 +19% |
✅ Reasons to believe
- 72% of analysts rate it a buy (Buy consensus, 18 ratings) — a sign of market conviction.
- Median price target $459, i.e. +15% from the current price ($399).
- The most reliable firm on ELV, Morgan Stanley (70% hit rate, 23 scored calls), targets $404 (call made on June 4, 2026, maturing on June 4, 2027) (+1%) in its most recent call, and $352 (call made on December 18, 2025, maturing on December 18, 2026) (-12%) in the one coming due soonest.
- 9 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (1.6% yield), raised for 14 years — regular income on top of potential upside.
- Reasonable valuation (P/E ~18) relative to its sector.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 18 ratings, 5 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on ELV
Median target $459 (+15%) · 18 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Elevance Health now?
We won't decide for you. The facts: 72% of analysts rate it a buy, median target $459 (+15%), and Morgan Stanley (most reliable on ELV, 70%) targets $404. Weigh that against valuation (P/E ~18). This is not personalized advice.
Is it too late to invest in Elevance Health?
Not according to analysts: the median target ($459) is still +15% above the current price ($399) (most reliable on ELV: Morgan Stanley, 70%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Elevance Health still worth investing in?
It depends on the gap between the price ($399) and its estimated value: analysts target $459 on median (+15%), with 72% buys (most reliable on ELV: Morgan Stanley, 70%). Cross-check with their real reliability on ELV and the cautions above. Information, not advice.
What's the main risk in buying ELV?
The consensus is not unanimous: of 18 ratings, 5 are neutral.
→ Go deeper: the full Elevance Health profile (consensus, analyst reliability, price target, performance).